A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 22 Sep 2017 According to EudraCT record, this trial was also planned in Australia, Finland and Germany.
    • 11 Sep 2017 Results from this study presented at the 18th Congress of the International Headache Society 2017, according to The International Headache Society media release.
    • 07 Sep 2017 According to an Amgenmedia release, primary endpoint has been met. (Change from baseline in total exercise time during an exercise treadmill test in subjects with stable angina.)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top